CD40 and breast carcinoma: Our test of this hypothesis by systemic treatment of the E0771 orthotopic breast cancer model with a combination of venetoclax and an anti-CD40 agonist showed that this combination reduced tumor growth rate and increased overall survival with 60% of mice surviving for >12 months (Fig. 3g).